Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30173% above fair value
$26.69+0.28 (+1.06%)
Close on Nov 18, 2026Market cap $1.72BP/E –Yield –
Stoke Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Stoke Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $27.59M, down 86.2% year over year. For fiscal 2025 it was $184.42M, up 404.5% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.42M | +404.5% |
| FY2024 | Dec 31, 2024 | $36.56M | +316.3% |
| FY2023 | Dec 31, 2023 | $8.78M | -29.2% |
| FY2022 | Dec 31, 2022 | $12.41M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.33M | -32.5% |
| Q1 FY2026 | Mar 31, 2026 | $6.23M | -96.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.40M | -93.8% |
| Q3 FY2025 | Sep 30, 2025 | $10.63M | +117.2% |
| Q2 FY2025 | Jun 30, 2025 | $13.82M | +186.0% |
| Q1 FY2025 | Mar 31, 2025 | $158.57M | +3661.1% |
| Q4 FY2024 | Dec 31, 2024 | $22.61M | +707.1% |
| Q3 FY2024 | Sep 30, 2024 | $4.89M | +47.9% |
| Q2 FY2024 | Jun 30, 2024 | $4.83M | – |
| Q1 FY2024 | Mar 31, 2024 | $4.22M | -18.2% |
| Q4 FY2023 | Dec 31, 2023 | $2.80M | -14.3% |
| Q3 FY2023 | Sep 30, 2023 | $3.31M | +13.9% |
| Q2 FY2023 | Jun 30, 2023 | -$2.48M | -176.8% |
| Q1 FY2023 | Mar 31, 2023 | $5.15M | +71.7% |
| Q4 FY2022 | Dec 31, 2022 | $3.27M | – |
| Q3 FY2022 | Sep 30, 2022 | $2.91M | – |
| Q2 FY2022 | Jun 30, 2022 | $3.23M | – |
| Q1 FY2022 | Mar 31, 2022 | $3.00M | – |
See a number that looks wrong?